$NVMDF News

Last published 4y ago

4y agoNUMIF NVMDFNovamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.ACCESS NewswireTORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously anno
4y agoNVMDFNovamind Shareholders Approve Proposed Acquisition by NuminusACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Numinus shareholders, at a separate meeting held today, have also
4y agoNVMDFNovamind Announces New Patient Financing OptionsACCESS NewswireTORONTO, ON / ACCESSWIRE / June 2, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced new patient financing options to help patients acce
4y agoNVMDFNovamind Reports Fiscal Q3 2022 Financial Results and Operating HighlightsACCESS NewswireRecord high quarterly revenue of $3,227,352, +32% over the previous quarter Growth driven by Arizona acquisition, expanding clinic network to eight total locations Numinus to acquire Novamind, creating a preeminent North American platform, spanning 13
4y agoNVMDFIndependent Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders of Novamind Vote FOR the Proposed Plan of ArrangementACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / May 27, 2022 / Novamind Inc.(CSE:NM)(OTC
4y agoNVMDFNovamind Launches Group Psychedelic Treatment for Frontline WorkersACCESS NewswireFollowing successful clinical pilot, treatment becomes regular offering at Novamind clinics TORONTO, ON / ACCESSWIRE / May 19, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized
4y agoNVMDFNovamind Files Management Information Circular for Special Meeting of Shareholders and Announces Receipt of Interim Court Order for Plan of ArrangementACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. Shareholders are encouraged to vote their common shares prior to th
4y agoBNOX NVMDFNovamind to Host Bionomics' PREVAIL Trial for Acute Treatment of Social Anxiety DisorderACCESS NewswireTORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for th
4y agoNVMDFNovamind Announces Virtual Group Health CoachingACCESS NewswireCollaboration with HealCommunity Offers Remote Access to Reimbursable Group Therapy Option TORONTO, ON / ACCESSWIRE / May 2, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized i
4y agoNUMIF NVMDFNuminus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and ResearchACCESS Newswire• Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory• Shared mission of responsibly reintroducing psychedelic therapy to m
4y agoNUMIF NVMDFNuminus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and ResearchPR NewswireComplementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to menta
4y agoNVMDFNovamind Opens 8th Integrative Psychiatry ClinicACCESS NewswireNew clinic in Phoenix, AZ, offers innovative mental health treatments and group therapy TORONTO, ON / ACCESSWIRE / April 6, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in
4y agoNVMDFNovamind Partner to Acquire Specialized Ibogaine Group in BrazilACCESS NewswireBienstar Plans To Build LATAM's First Network of Integrative Mental Health Clinics TORONTO, ON / ACCESSWIRE / March 31, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psy
4y agoNVMDFNovamind Expands Group Therapy ModelACCESS NewswireInnovative in-person and virtual group offerings increase access to care and social connection TORONTO, ON / ACCESSWIRE / March 24, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specia
4y agoMNMD NVMDFNovamind to Host MindMed Phase IIb Trial for LSD and AnxietyACCESS NewswireTORONTO, ON / ACCESSWIRE / March 16, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce it has been selected by Mind Medicine, Inc
4y agoNVMDFNovamind Grants Restricted Share UnitsACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / March 11, 2022 / Novamind Inc. (CSE:NM)(
4y agoNVMDFNovamind to Conduct Phase II Psilocybin Trial for Major Depressive DisorderACCESS NewswireFirst patient randomization completed at Draper, Utah research site TORONTO, ON / ACCESSWIRE / March 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicin
4y agoATAI CYBN ENVB FTRP+3Benzinga Expands Footprint into the Psychedelic Industry with the Launch of the Benzinga Psychedelic Advisory CouncilPR NewswireDETROIT, March 4, 2022 /PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought leaders sharing insights into industry developments, sector trends and br
4y agoNVMDFNovamind Reports Fiscal Q2 2022 Financial Results and Operating HighlightsACCESS NewswireRecord high revenue of $2,452,540, +32% over the previous quarter Opened new outpatient clinic located in downtown Salt Lake City Strong pipeline of clinical trials for psychedelics and mental health treatments In January 2022, successfully closed th
4y agoNVMDFNovamind Publishes Psychedelic Therapy Patient Case StudiesACCESS NewswireTORONTO, ON / ACCESSWIRE / February 22, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched Healing Stories, a series of case studies with f
4y agoNVMDFNovamind Advances Clinical Pilot for Frontline KAPACCESS NewswireInnovative treatment is a candidate to become regular service offering for healthcare workers TORONTO, ON / ACCESSWIRE / February 16, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company spec
4y agoNVMDFNovamind Participates in Alto Neuroscience Phase II Clinical Trial for MDD and PTSDACCESS NewswireClinical trial underway at Novamind's Draper, UT research site TORONTO, ON / ACCESSWIRE / February 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine,
4y agoNVMDFNovamind Appoints Prakash Gowd as Chief Operating OfficerACCESS NewswireTORONTO, ON / ACCESSWIRE / February 8, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that Prakash Gowd has been appointed as
4y agoNVMDFNovamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life PatientsACCESS NewswireTORONTO, ON / ACCESSWIRE / February 3, 2022 / Novamind Inc. (CSE:NM, OTCQB:NVMDF, FSE:HN2))) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected by the Ketamine Research
4y agoNVMDFNovamind Announces Closing of CAD$5 Million Private Placement with Institutional InvestorACCESS NewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESSWIRE / January 26, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialize
4y agoNVMDFNovamind Announces CAD$5 Million Private Placement with Institutional InvestorACCESS NewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESSWIRE / January 24, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialize
4y agoNVMDFNovamind to Participate in Citi's Psychedelic Drug Video Call SeriesACCESS NewswireTORONTO, ON / ACCESSWIRE / January 20, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that it will participate in Citi's Psychedelic
4y agoNVMDFNovamind Closes Arizona AcquisitionACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / January 18, 2022 / Novamind Inc. (CSE:NM
4y agoNVMDFNovamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use DisorderACCESS NewswireTORONTO, ON / ACCESSWIRE / January 13, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it will host a phase I randomized clinical tria
4y agoNVMDFNovamind Unveils New Design Concept for ClinicsACCESS NewswireTORONTO, ON / ACCESSWIRE / January 5, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the "Design Concept")
4y agoNVMDFNovamind Signs Definitive Agreement to Acquire Arizona-based ClinicsACCESS NewswireNot for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. TORONTO, ON / ACCESSWIRE / December 23, 2021 / Novamind Inc. (CSE:N
4y agoCYBN MCURF NVMDFWhy Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental TherapiesPR NewswirePALM BEACH, Fla., Dec. 16, 2021 /PRNewswire/ -- Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing mental health disorders. More and more psychedelic-assisted psychotherapy clinics,
4y agoNVMDFNovamind Opens New Clinic with Specialized Focus on Substance Use DisordersACCESS NewswireSalt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza TORONTO, ON / ACCESSWIRE / December 6, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in p
4y agoNVMDFNovamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6ACCESS NewswireTORONTO, ON / ACCESSWIRE / December 2, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will present at the virtual H.C. Wainwright 2nd Annual Psychede
4y agoNVMDFNovamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic NetworkACCESS NewswireStrategic investment and advisory agreement enables the global expansion of Novamind's psychedelic clinic model TORONTO, ON / ACCESSWIRE / December 1, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental he
4y agoNVMDFNovamind Reports Fiscal Q1 Financial Results and Operating HighlightsACCESS NewswireMultistate expansion underway, signed LOI to acquire Arizona-based mental health practice Total revenue of $1,857,750, +113% when compared to same period last year Total working capital of $6,834,011 to fund operations TORONTO, ON / ACCESSWIRE / Nov
4y agoNVMDFNovamind Unveils New Logo and Invests in Unified BrandACCESS NewswireTORONTO, ON / ACCESSWIRE / November 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today launched a new logo and announced that the Company will
4y agoNVMDFNovamind Signs LOI to Acquire Two Mental Health Clinics in ArizonaACCESS NewswireTORONTO, ON / ACCESSWIRE / November 16, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it has signed a Letter of Intent ("LOI")
4y agoNVMDFNovamind to Present at International Summit on Psychedelic Therapies for Mental IllnessACCESS NewswireTORONTO, ON / ACCESSWIRE / November 15, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will participate in Mind Medicine Australia's International Su
5y agoNVMDFNovamind Enters New Lease Agreement Responding to Patient DemandACCESS NewswireTORONTO, ON / ACCESSWIRE / November 12, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today it has leased a new clinic location in Utah (t
5y agoNVMDFNovamind Secures Insurance Coverage for Ketamine from Four Major PayorsACCESS NewswireBlue Cross added to list of insurance companies covering IV ketamine treatments at Novamind TORONTO, ON / ACCESSWIRE / November 10, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specia
5y agoNVMDFNovamind Announces Revocation of Cease Trade Order and Reinstatement of TradingACCESS NewswireTORONTO, ON / ACCESSWIRE / November 8, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that the Ontario Securities Commission (the "
5y agoNVMDFNovamind Reports FY2021 Financial Results and Operating HighlightsACCESS NewswireIndustry-leading revenue, $6,069,247 in FY2021 Total working capital of $9,680,431 to fund operations Expanded network to six clinics and three clinical research sites Contracted for eight clinical trials Granted DEA Schedule 1 licenses for psil
5y agoNVMDFNovamind Announces Cease Trade Order and Delay in Filing Annual Financial StatementsACCESS NewswireTORONTO, ON / ACCESSWIRE / November 4, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it is the subject of a failure-to-
5y agoNVMDFNovamind Unveils Stealth Mode Investment in Alto NeuroscienceACCESS NewswireTORONTO, ON / ACCESSWIRE / October 22, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to unveil Alto Neuroscience ("Alto"), a clinical-sta
5y agoAWKNF BETRF BMBIF CYBN+16KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand ViewingPR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
5y agoNVMDFNovamind Granted DEA Licenses for Psilocybin ResearchACCESS NewswireLicenses a key step in hosting contracted clinical trials for Schedule 1 controlled substances TORONTO, ON / ACCESSWIRE / October 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company spec
5y agoAWKNF BETRF BMBIF CYBN+13KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14thPR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional inves
5y agoNVMDFNovamind to Present at LD Micro and KCSA ConferencesACCESS NewswireTORONTO, ON / ACCESSWIRE / October 8, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced participation in two upcoming virtual investor c
5y agoNVMDFNovamind Launches New Psychedelic Palliative Care ProgramACCESS NewswireSpecialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illness TORONTO, ON / ACCESSWIRE / October 7, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"